Suppr超能文献

口服递呈治疗性肽和蛋白质:基于脂质的纳米载体技术全景。

Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers.

机构信息

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.

Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Medical Biomaterial Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Adv Drug Deliv Rev. 2022 Mar;182:114097. doi: 10.1016/j.addr.2021.114097. Epub 2022 Jan 7.

Abstract

The oral administration of therapeutic peptides and proteins is favoured from a patient and commercial point of view. In order to reach the systemic circulation after oral administration, these drugs have to overcome numerous barriers including the enzymatic, sulfhydryl, mucus and epithelial barrier. The development of oral formulations for therapeutic peptides and proteins is therefore necessary. Among the most promising formulation approaches are lipid-based nanocarriers such as oil-in-water nanoemulsions, self-emulsifying drug delivery systems (SEDDS), solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), liposomes and micelles. As the lipophilic character of therapeutic peptides and proteins can be tremendously increased such as by the formation of hydrophobic ion pairs (HIP) with hydrophobic counter ions, they can be incorporated in the lipophilic phase of these carriers. Since gastrointestinal (GI) peptidases as well as sulfhydryl compounds such as glutathione and dietary proteins are too hydrophilic to enter the lipophilic phase of these carriers, the incorporated therapeutic peptide or protein is protected towards enzymatic degradation as well as unintended thiol/disulfide exchange reactions. Stability of lipid-based nanocarriers towards lipases can be provided by the use to excipients that are not or just poorly degraded by these enzymes. Nanocarriers with a size <200 nm and a mucoinert surface such as PEG or zwitterionic surfaces exhibit high mucus permeating properties. Having reached the underlying absorption membrane, lipid-based nanocarriers enable paracellular and lymphatic drug uptake, induce endocytosis and transcytosis or simply fuse with the cell membrane releasing their payload into the systemic circulation. Numerous in vivo studies provide evidence for the potential of these delivery systems. Within this review we provide an overview about the different barriers for oral peptide and protein delivery, highlight the progress made on lipid-based nanocarriers in order to overcome them and discuss strengths and weaknesses of these delivery systems in comparison to other technologies.

摘要

从患者和商业角度来看,口服给予治疗性肽和蛋白质是有利的。为了在口服给药后到达体循环,这些药物必须克服许多障碍,包括酶、巯基、粘液和上皮屏障。因此,有必要开发治疗性肽和蛋白质的口服制剂。最有前途的制剂方法之一是基于脂质的纳米载体,如油包水纳米乳、自乳化药物传递系统 (SEDDS)、固体脂质纳米粒 (SLN)、纳米结构脂质载体 (NLC)、脂质体和胶束。由于治疗性肽和蛋白质的亲脂性可以通过与疏水性抗衡离子形成疏水性离子对 (HIP) 而大大增加,因此它们可以被包含在这些载体的亲脂相中。由于胃肠道 (GI) 肽酶以及谷胱甘肽和膳食蛋白质等巯基化合物过于亲水而无法进入这些载体的亲脂相,因此包含的治疗性肽或蛋白质可以防止酶降解和意外的硫醇/二硫键交换反应。通过使用不易被这些酶降解或仅被轻微降解的赋形剂,可以为脂质纳米载体提供对脂肪酶的稳定性。粒径<200nm 且具有黏液惰性表面(如 PEG 或两性离子表面)的纳米载体具有很高的黏液穿透特性。到达下面的吸收膜后,基于脂质的纳米载体能够实现细胞旁和淋巴摄取药物,诱导内吞作用和转胞吞作用,或者简单地与细胞膜融合,将其有效载荷释放到体循环中。许多体内研究为这些递送系统的潜力提供了证据。在这篇综述中,我们概述了口服肽和蛋白质递送的不同障碍,强调了为克服这些障碍而在基于脂质的纳米载体方面取得的进展,并讨论了这些递送系统与其他技术相比的优缺点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验